细胞色素P450 2C19基因分型与质子泵抑制剂——聚焦雷贝拉唑
CYP2C19 genotype and the PPIs--focus on rabeprazole.
作者信息
Lim P W Y, Goh K L, Wong B C Y
机构信息
Eisai Co., Ltd, c/o Eisai Asia Regional Services Pte Ltd, Singapore.
出版信息
J Gastroenterol Hepatol. 2005 Dec;20 Suppl:S22-8. doi: 10.1111/j.1440-1746.2005.04167.x.
Abstract
Amongst all the proton pump inhibitors (PPI), the hepatic metabolism of rabeprazole is least dependent on the CYP4502C19 system. Rabeprazole is therefore the PPI least affected by CYP4502C19 genetic polymorphism. This unique feature of rabeprazole complements rabeprazole's fast onset of action, and may lead to profound and consistent inhibition of gastric acid secretion in the treatment of acid-related disorders.
摘要
在所有质子泵抑制剂（PPI）中，雷贝拉唑的肝脏代谢对CYP4502C19系统的依赖性最小。因此，雷贝拉唑是受CYP4502C19基因多态性影响最小的PPI。雷贝拉唑的这一独特特性与它起效迅速相辅相成，在治疗酸相关性疾病时，可能会对胃酸分泌产生强效且持续的抑制作用。
Zotero 插件